Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663442 · ClinicalTrials.gov registry record · Phase 4
Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 4 study of ADHD, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00663442 is a Phase 4 study of ADHD that has completed, run by University of Illinois at Chicago. The registered enrollment target is 48 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00663442, a Phase 4 study of ADHD, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted. Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response
Conditions Studied
Interventions
- DRUG OROS methylphenidate
Study Locations (1)
Illinois
- HALP Clinic, University of Illinois at CHicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 1999-12 |
| Est. Completion | 2004-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663442
The ClinicalTrials.gov registry entry for NCT00663442 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (75% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which OROS methylphenidate is the first listed.
NCT00663442 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00663442 about?
NCT00663442 is a clinical study titled "Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)". Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week...
What is the current status of trial NCT00663442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 1999-12. Estimated completion is 2004-11.
What conditions does trial NCT00663442 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT00663442?
The interventions under investigation include: OROS methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00663442?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00663442 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
Evaluating Treatment of ADHD in Children with Down Syndrome
RECRUITING · Phase 4
-
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
RECRUITING · Phase 4
-
AWARE: Management of ADHD in Autism Spectrum Disorder
RECRUITING · Phase 4
-
Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom
ACTIVE NOT RECRUITING · Phase 4
-
A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.